Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-969

QUOTES THAT MATTER- not faceless non holding posters.

"Remestemcel-L suppresses activity of allo-reactive T cells that are causing a hyperinflammatory state and attacking various tissue in GVHD. I have seen remestemcel-L cure children with acute GvHD who have failed to respond to all standard therapies. I sincerely hope that this BLA is approved by the FDA with this resubmission," Joanne Kurtzberg, MD, professor of pediatrics and pathology, director of Marcus Center for Cellular Cures, Pediatric Blood and Marrow Transplant Program, and Carolinas Cord Blood Bank, and co-director, of Stem Cell Transplant Laboratory Duke University Medical Center, told Targeted Oncology^TM.


Reg